# Exelixis

Source: https://onco.cc/companies/exelixis/  
OnCo record `exelixis` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.

## Summary

Exelixis, based in Alameda, California, and listed as EXEL, makes cabozantinib, sold as Cabometyx, which is used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers. Cabozantinib is approved in renal cell carcinoma alone and with nivolumab, in hepatocellular carcinoma after sorafenib on the CELESTIAL trial, in differentiated thyroid cancer, and in advanced pancreatic and extra-pancreatic neuroendocrine tumours on the CABINET trial in March 2025, and the next-generation kinase inhibitor zanzalintinib is in phase 3 in colorectal cancer and neuroendocrine tumours. OnCo also links it to adrenocortical carcinoma and osteosarcoma. Whether zanzalintinib can extend the franchise beyond cabozantinib is the open question. Cabozantinib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Alameda, CA
- Type: biotech
- Website: https://www.exelixis.com
- Ticker: EXEL

## Notes

- Zanzalintinib (XL092) is in phase 3 across kidney cancer with belzutifan (LITESPARK-034), colorectal cancer (STELLAR-303) and neuroendocrine tumours; XB002 is the company's antibody-drug conjugate.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Exelixis
- Official website: https://www.exelixis.com

## Connected records

- cancers: [Adrenocortical carcinoma](https://onco.cc/cancers/adrenocortical/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- trials: [A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va](https://onco.cc/trials/nct03690388/), [A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)](https://onco.cc/trials/nct05859217/), [CABONE](https://onco.cc/trials/cabone/), [Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A](https://onco.cc/trials/nct01639508/), [Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies](https://onco.cc/trials/nct03539822/), [CELESTIAL](https://onco.cc/trials/celestial/), [CheckMate 9ER](https://onco.cc/trials/checkmate-9er/), [COMET-1](https://onco.cc/trials/comet-1/), [CONTACT-03](https://onco.cc/trials/contact-03/), [COSMIC-313](https://onco.cc/trials/cosmic-313/), [EXAM](https://onco.cc/trials/exam/), [Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study](https://onco.cc/trials/nct07620574/), [Pan Tumor Rollover Study](https://onco.cc/trials/nct03899155/), [PAPMET (SWOG S1500)](https://onco.cc/trials/papmet/), [Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC](https://onco.cc/trials/nct04446117/), [Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece](https://onco.cc/trials/nct03755791/), [Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05425940/), [Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06082167/), [Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease](https://onco.cc/trials/nct07750158/), [Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors](https://onco.cc/trials/nct06943755/)

---
JSON: https://onco.cc/api/v1/entities/exelixis.json